Prof. Dr. Hasan Mutlu

Formation et spécialisation

• Hacettepe Üniversitesi Tıp Fakültesi — Études de médecine
• 1999 Akdeniz Üniversitesi — Spécialisation en médecine interne
• Akdeniz Üniversitesi Tıp Fakültesi — Spécialisation en oncologie médicale

Expérience

• Akdeniz Üniversitesi Tıp Fakültesi
• Medical Park Antalya

Principaux domaines d’intérêt

• Diagnostic des tumeurs d’organes
• Chimiothérapie
• Thérapies ciblées et immunothérapie
• Analyses génétiques de nouvelle génération
• Recherche scientifique en oncologie

Sélection de publications scientifiques

• Tural D, Akar E, Mutlu H, Kilickap S. P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther. 2014 Sep;14(9):1089-96. doi: 10.1586/14737140.2014.929946. Epub 2014 Jun 26.
• Mutlu H, Bozcuk H, Artaç M, Eser İ. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis. J Cancer Res Ther. 2023 Apr;19(Supplement):S6-S11. doi: 10.4103/jcrt.jcrt_721_21.
• Bozcuk H, Artaç M, Mutlu H, Sever Ö, Yıldırım M. Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. J Oncol Pharm Pract. 2021 Mar;27(2):405-413. doi: 10.1177/1078155220964903. Epub 2020 Oct 12.
• Mutlu H, Bozcuk H. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. J Cancer Res Ther. 2023 Jan-Mar;19(2):394-402. doi: 10.4103/jcrt.JCRT_23_20.
• Bozcuk H, Yıldırım M, Sever Ö, Mutlu H, Artaç M. Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis. J Cancer Res Ther. 2020 Jul-Sep;16(4):828-837. doi: 10.4103/jcrt.JCRT_450_19.
• Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Coşkun HŞ. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract. 2016 Dec;22(6):806-810. doi: 10.1177/1078155215611048. Epub 2015 Oct 13.
• Musri FY, Mutlu H, Eryilmaz MK, Salim DK, Tazegul G, Coşkun HŞ. Hypercalcemia associated with squamous cell carcinoma of renal pelvis: A case and review of the literature. J Cancer Res Ther. 2019 Mar;15(Supplement):S170-S172. doi: 10.4103/0973-1482.187236.
• Bozcuk H, Coşkun HŞ, İlhan Y, Göksu SS, Yıldız M, Bayram S, Yerlikaya T, Koçer M, Artaç M, Uğraklı M, Ouisupov A, Aydeniz A, Şahin D, Yalçın G, Saatçi M, Mutlu H, Yıldırım M. Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy. Support Care Cancer. 2022 Mar;30(3):2621-2629. doi: 10.1007/s00520-021-06681-0. Epub 2021 Nov 23.
• Mutlu H, Akca Z, Erden A, Aslan T, Ucar K, Kaplan B, Buyukcelik A. Lack of sunlight exposure influence on primary glioblastoma survival. Asian Pac J Cancer Prev. 2014;15(10):4165-8. doi: 10.7314/apjcp.2014.15.10.4165.
• Mutlu H, Akca Z, Cihan YB, Kurnaz F, Aslan T, Erden A, Ugur H, Aksahin A, Buyukcelik A. Is season a prognostic factor in breast cancer? Asian Pac J Cancer Prev. 2013;14(2):743-6. doi: 10.7314/apjcp.2013.14.2.743.
• Alemdar MS, Çolak Y, Günbayı İ, Mutlu H. The Use of Artificial Intelligence Chatbots by Newly Diagnosed Cancer Patients: A Descriptive Phenomenological Study. Curr Oncol. 2026 Sep 17;33(9):563. doi: 10.3390/curroncol33090563.
• Mutlu H, Musri FY, Artaç M, Kargi A, Özdogan M, Bozcuk H. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. J Cancer Res Ther. 2015 Apr-Jun;11(2):287-90. doi: 10.4103/0973-1482.154008.
• Oguz A, Unal D, Kurtul N, Aykas F, Mutlu H, Karagoz H, Cetinkaya A. Season of diagnosis and survival of advanced lung cancer cases--any correlation? Asian Pac J Cancer Prev. 2013;14(7):4325-8. doi: 10.7314/apjcp.2013.14.7.4325.
• Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? J Cancer Res Ther. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933.
• Musri FY, Mutlu H, Eryilmaz MK, Salim DK, Gunduz S, Coskun HS. The Neutrophil to Lymphocyte Ratio is an Independent Prognostic Factor in Patients with Metastatic Gastric Cancer. Asian Pac J Cancer Prev. 2016;17(3):1309-12. doi: 10.7314/apjcp.2016.17.3.1309.
• Eryilmaz MK, Mutlu H, Tazegul G, Eryılmaz R, Müsri FY, Salim DK, Ünal B, Coşkun HŞ. Multiple pelvic cysts in a patient with familial Mediterranean fever: Benign cystic mesothelioma. J Cancer Res Ther. 2017 Oct-Dec;13(6):1047-1049. doi: 10.4103/jcrt.JCRT_125_16.
• Cihan YB, Ozturk A, Mutlu H. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev. 2014;15(5):2061-7. doi: 10.7314/apjcp.2014.15.5.2061.
• Mutlu H, Büyükçelik A, Akça Z, Kaya N. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor. J Oncol Pharm Pract. 2014 Aug;20(4):298-301. doi: 10.1177/1078155213495286. Epub 2013 Aug 8.
• Eryilmaz MK, Mutlu H, Ünal B, Salim DK, Musri FY, Coşkun HŞ. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. J Cancer Res Ther. 2018 Apr-Jun;14(3):619-624. doi: 10.4103/0973-1482.174550.
• Gunduz S, Mutlu H, Goksu SS, Arslan D, Tatli AM, Uysal M, Coskun HS, Bozcuk H, Ozdogan M, Savas B. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma. Asian Pac J Cancer Prev. 2014;15(20):8843-6. doi: 10.7314/apjcp.2014.15.20.8843.
• Müsri FY, Mutlu H, Karaağaç M, Eryilmaz MK, Gündüz Ş, Artaç M. Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer. J Gastric Cancer. 2016 Jun;16(2):78-84. doi: 10.5230/jgc.2016.16.2.78. Epub 2016 Jun 24.
• Musri FY, Mutlu H, Kıvrak Salim D, Karakurt Eryılmaz M, Ünal B, Tural D, Şenol Coşkun H. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer. J Oncol Pharm Pract. 2016 Apr;22(2):350-3. doi: 10.1177/1078155214565126. Epub 2015 Jan 6.
• Cihan YB, Baykan H, Kavuncuoglu E, Mutlu H, Kucukoglu MB, Ozyurt K, Oguz A. Relationships between skin cancers and blood groups--link between non-melanomas and ABO/Rh factors. Asian Pac J Cancer Prev. 2013;14(7):4199-203. doi: 10.7314/apjcp.2013.14.7.4199.
• Oguz A, Unal D, Tasdemir A, Karahan S, Aykas F, Mutlu H, Cihan YB, Kanbay M. Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev. 2013;14(1):453-6. doi: 10.7314/apjcp.2013.14.1.453.
• Mutlu H, Akca Z, Teke HU, Ugur H. Evaluation of Peripheral Blood Smear for Myelodysplasia in Breast Cancer Patients who Received Adjuvant Antracycline. Eurasian J Med. 2011 Dec;43(3):173-6. doi: 10.5152/eajm.2011.36.